Navigation Links
Developing a modular, nanoparticle drug delivery system

There are two aspects to creating an effective drug: finding a chemical compound that has the desired biological effect and minimal side-effects and then delivering it to the right place in the body for it to do its job.

With the support from a $478,000, five-year CAREER award from the National Science Foundation, Eva Harth is tackling the second part of this problem. She is creating a modular, multi-functional drug delivery system that promises simultaneously to enhance the effectiveness and reduce undesirable side-effects of a number of different drugs.

(NSFs Faculty Early Career Development awards are the agencys most prestigious honor for junior faculty members and are given to individuals judged most likely to become the academic leaders of the 21st century.)

Harth, who is an assistant professor of chemistry at Vanderbilt University, has created a nanosponge specially designed to carry large numbers of drug molecules. She has also discovered a molecular transporter that, when attached to the nanosponge, carries it and its cargo across biological barriers into specific intracellular compartments, which are very difficult places for most drugs to reach. She has shown that her system can reach another difficult target: the brain. Experiments have shown that it can pass through the brain-blood barrier. In addition, she has: successfully attached a special targeting unit that delivers drugs to the surface of tumors in the lungs, brain and spinal cord and even developed a light kit for her delivery system fluorescent tags that researchers can use to monitor where it goes.

Harth has taken a different approach from other researchers working on nanotechnology for drug development. Instead of trying to encapsulate drugs in nanoscale containers, she decided to create a nanoparticle that had a large number of surface sites where drug molecules could be attached. To do so, she adopted a method that uses extensive internal cross-linking to scrunch a long, linear molecule into a sphere about 10 nanometers in diameter, about the size of a protein. Nanoparticles like this are called nanosponges.

We can really load this up with a large number of drug molecules, she says.

Working with Heidi Hamm, the Earl W. Sutherland Jr. Professor of Pharmacology at Vanderbilt, Harth synthesized a dendritic molecule with the ability to slip through cell membranes and reach the cell nucleus. They figured out how to attach this transporter to her nanoparticle and showed that the transporter can pull the nanoparticle after it into cellular compartments. They also demonstrated that the transporter can deliver large molecules specifically peptides and proteins into specific sub-cellular locations.

Peptides and proteins can act as drugs, just like smaller molecules, Harth says. However, there is not much activity in this area because people havent had a method for getting them into cells. Now that there is a way to do it, but that may change.

Hamm studies G proteins, arguably the most important signaling molecules in the cell. Scientists think that many diseases, including diabetes and certain forms of pituitary cancer, are caused by malfunctioning G proteins. She and Harth are collaborating on using the transporter to deliver peptides produced by G proteins that disrupt signaling pathways.

Evas methods for drug delivery are very novel and versatile and can be adapted to delivery of proteins, peptides, DNA and smaller chemical compounds like most drugs. The breadth of applications makes her technology very powerful, Hamm says.

The chemist is also collaborating with Dennis E. Hallahan, professor of radiation oncology at Vanderbilt, to apply the drug delivery system to fighting cancer. Hallahans lab had identified a molecule that targets a surface feature on lung carcinomas. Harth took the molecule, improved it, attached it to her nanoparticle and the two of them determined that the combination is capable of delivering drugs to the surface of lung tumors.

She is now working with Hallahan to adapt her delivery system to carry cisplatinum, a traditional chemotherapy agent that is used to treat a number of different kinds of cancer but is highly toxic and has a number of unpleasant side effects.

By delivering the anti-cancer agent directly to the cancerous tissues, Evas system decreases the adverse effects on other tissues and increases its potency by delivering a higher concentration of the drug directly on the cancer, Hallahan explains.

The people in my lab have tried at a number of different drug delivery systems and Evas works the best of those weve looked at, Hallahan says.

Vanderbilt is applying for two patents on the system.


Contact: David F. Salisbury
Vanderbilt University

Related medicine news :

1. New antibiotic already developing resistance
2. Identifying The Risks Of Developing Schizophrenia
3. Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
4. Risk Of Developing Arthritis
5. Periodontal disease may amass the risk of developing Type 2 diabetes
6. Developing HIV fighter
7. Diabetes cases could double in developing countries in next 30 years
8. Antibiotics Found To Increase The Risk Of Developing Breast Cancer
9. The Effectiveness Of Cancer Drug In Women At Risk Of Developing Cancer
10. Men Who at Risk Of Developing Prostate Cancer
11. Cancer Patients At A Greater Risk Of Developing Blood Clots
Post Your Comments:
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk ... roadways has dropped below 10,000 for the first time since 2011. In 2014, there ... According to data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people ...
(Date:11/25/2015)... ... November 25, 2015 , ... In honor of ... Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension (PH) patients ... by the public, will receive special recognition throughout 2016 as part of PHA’s ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract ... significant expansion of its current state of the art research, development and manufacturing ... to increase its manufacturing capacity as well as to support its clients’ growing ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of the common symptoms of ... and dry skin. But many people who find their cholesterol levels and weight are ... their thyroid, especially if they don’t have any of the other symptoms. , Thyroid ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY USA ... continues to provide evidence demonstrating the accuracy of its ... Congress on Insulin Resistance, Diabetes and Cardiovascular Disease in ... both the Company,s GLUCOCARD ® 01 meter and ... accuracy requirements. The ability to accurately measure glucose levels ...
(Date:11/25/2015)... 25, 2015 Kitov Pharma ... KTOV), a biopharmaceutical company focused on the development of ... conditions, today announced the closing of its previously announced ... ADSs ), each representing 20 ordinary shares of the ... The ADSs and warrants were issued in a fixed ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Trovagene, ... molecular diagnostics, today announced that Chief Executive Officer Antonius ... at the 27 th Annual Piper Jaffray Healthcare ... Conference at the New York Palace Hotel in ... 2015 at 1:30 p.m. EST. Mr. Schuh will be ...
Breaking Medicine Technology: